Endogenous tissue-type plasminogen activator and risk of myocardial infarction.
about
Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factorsA new device for measurement of fibrin clot lysis: application to the euglobulin clot lysis timeThe current role and future prospects of D-dimer biomarkerHemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analysesThe prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balanceClinical methods for the evaluation of endothelial function-- a focus on resistance arteries.Proteomic analysis of differential protein expression in atherosclerosis.Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction.Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart diseasePleiotropic functions of plasminogen activator inhibitor-1.Testing for endothelial dysfunction.Coronary Heart Disease in Postmenopausal Women with Type II Diabetes Mellitus and the Impact of Estrogen Replacement Therapy: A Narrative Review.Increased tissue plasminogen activator levels in patients with nonvalvular atrial fibrillationEndothelium-derived hyperpolarizing factor mediates bradykinin-stimulated tissue plasminogen activator release in humans.Fluvastatin: effects beyond cholesterol lowering.Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia.Biomarkers and HIV-associated cardiovascular disease.Alcohol consumption and risk of deep venous thrombosis and pulmonary embolism in older persons.Endothelial dysfunction in the pathogenesis of atherosclerosis.Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention programGene polymorphisms of the haemostatic system and the risk of arterial thrombotic disease.The relationship between infection, inflammation, and cardiovascular disease: an overview.Endothelial dysfunction in children with type 1 diabetes mellitus.Obesity, haemostasis and the fibrinolytic system.The Association of the Metabolic Syndrome with PAI-1 and t-PA LevelsThe effects of postmenopausal hormone replacement therapy on hemostatic variables: a meta-analysis of 46 studies.Influence of dietary saturated fat intake on endothelial fibrinolytic capacity in adults.Novel family-based approaches to genetic risk in thrombosis.Inflammatory and thrombotic mechanisms in coronary atherosclerosisvon Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction.Fibrinolytic potential is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia.Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels.Relation of C-reactive protein to endothelial fibrinolytic function in healthy adults.Are we content with lowering blood pressure alone, or should we be asking something more from the antihypertensive drugs we use?: effects of antihypertensive agents on fibrinolytic function.The metabolic syndrome: an emerging risk state for cardiovascular disease.Genetics of platelet glycoprotein receptors: risk of thrombotic events and pharmacogenetic implications.The plasminogen activator system modulates sympathetic nerve function.4G/5G polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome.Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin TherapySelf-reported habitual short sleep duration is associated with endothelial fibrinolytic dysfunction in men: a preliminary report.
P2860
Q24634779-14A6499E-B164-428D-98AC-9B6AF02E0F8EQ24791887-5DC7EB58-57D2-4B59-819D-E14784EDAFCFQ26741071-0E567AB0-4F51-49A0-8F1D-720F6998C15DQ26993237-25B7C1E1-DFC1-4736-BD7A-C070E3D09BFCQ27003277-36BFFA1F-0474-4045-97E3-B048159D9E42Q33242082-FEAC8335-227E-4017-9A53-31083311AF96Q33246067-5787A45D-9220-40CF-99AF-105CFF2FC6BFQ33597486-D0BB77CA-002D-4689-A4D6-E8CC668E46C7Q33613823-2A0E6416-081C-4202-99A1-3080D426C733Q33984228-AAE18B8D-9987-4F27-8DAB-C6A1791145B2Q34008359-FFE94C96-9588-4592-8E30-E9AA3F6D23FDQ34022283-4E28F5E5-310A-4B29-A1E7-57C57B409C34Q34025555-8795BFFB-CFB2-4502-AE80-69522280CF84Q34111633-2FC5AA8A-8DC3-40F0-A95A-CAF3AC99AD0CQ34126048-8ECD731F-2D2E-4F13-A3DE-1F964449DA89Q34144305-5F9EC636-A624-4F46-B7F9-700E7C2AAC4BQ34335486-50038B8E-BDA1-499C-A44B-AFE107A569B3Q34395534-5A346525-2E37-47EC-9A85-1B64FE943541Q34430443-FBCCF2F2-653E-450C-A255-9CAD798881DDQ34457386-29B42F97-9C27-429B-90D6-9E5591E2BEE0Q34459073-C4E3AB1E-C3E7-486E-A0AD-348983F5FAABQ34557639-FB2CFAA3-B2E4-4709-9E06-EBE7893C31F0Q34636106-95ED54D5-71CD-4AE4-B66E-9A47788582F2Q34743382-11AFAA72-D319-4BE5-B762-1F9AA55CEEDFQ34929646-33E9A8BC-64B5-4518-BC6C-1771464D5CCEQ34978893-7DE32597-CA45-407B-B59D-8957E6B0F16DQ35170392-23017941-2946-4998-8F93-AFD4C914084BQ35181584-32AF1B27-DAAD-478E-8550-4AF6FC202246Q35201247-D7FE0B49-E2FD-409A-8203-DE7501813EF8Q35368972-8F857E8B-11B6-4BA8-9A2D-CCEAD2C1842FQ35567290-2FE9E7C6-620C-44AC-A6D9-A29627205BBDQ35658814-8E920BF3-1E2F-46E6-9493-6D1D65DD085AQ35774550-5EC7A806-ECFC-440A-ACD5-44AE886BAA1AQ35816401-3B64DD2A-F5D5-44F2-A1DC-D4B86F16F6F3Q35824621-49149493-19BA-40A6-9F2D-4AB7744DFE59Q36094351-821974A1-E737-4F4C-89DC-77DEC0F91330Q36228900-7DCB4CE9-F32F-4172-8590-637D8E445A5AQ36268407-BE97E367-9A26-4A8F-B569-74EB5E03DEA9Q36520556-C84F3CC7-A2B7-4EDC-99BD-92E0480BE093Q36526467-8EE2AB9E-2AC7-45BB-95B0-453373E48EB9
P2860
Endogenous tissue-type plasminogen activator and risk of myocardial infarction.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Endogenous tissue-type plasminogen activator and risk of myocardial infarction.
@en
type
label
Endogenous tissue-type plasminogen activator and risk of myocardial infarction.
@en
prefLabel
Endogenous tissue-type plasminogen activator and risk of myocardial infarction.
@en
P2093
P1433
P1476
Endogenous tissue-type plasminogen activator and risk of myocardial infarction.
@en
P2093
C H Hennekens
D E Vaughan
J E Manson
M J Stampfer
P M Ridker
P304
P356
10.1016/0140-6736(93)90998-V
P407
P577
1993-05-01T00:00:00Z